Biosimilar Diplomacy By Other Means: GPhA CEO Calls Out Amgen Guest

During speech to the group’s annual meeting, GPhA President Ralph Neas says he is disappointed that Amgen, which is among the firms attending the gathering, is pushing biosimilar substitution restrictions in state legislatures.

ORLANDO – The Generic Pharmaceutical Association struck a combative tone at the start of its annual meeting, calling out two companies pushing legislation in states that could potentially limit biosimilar use, including one with a representative at the event.

GPhA President and CEO Ralph Neas used his Feb. 21 speech at the meeting to scold Amgen Inc. and Genentech Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America